Indexed in Journament

the lancet oncology

ISSN 1474-5488· EN

Certificate of Indexing
Login or register to claim ownership or editorship of this journal.
9
Articles Indexed

About This Journal

Short Name lancet oncol
Abbreviated Name lancet oncol
ISSN 1474-5488

Indexings

scopus ncbi

Tools & Certificate of Indexing

Certificate of Indexing

Publications Per Year

Articles (9)

2017
Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study
Chiappella A;Martelli M;Angelucci E;Brusamolino E;Evangelista A;Carella AM;Stelitano C;Rossi G;Balzarotti M;Merli F;Gaidano G;Pavone V;Rigacci L;Zaja F;D'Arco A;Cascavilla N;Russo E;Castellino A;Gotti M;Congiu AG;Cabras MG;Tucci A;Agostinelli C;Ciccone G;Pileri SA;Vitolo U;;
Vol. 18 , No. 8 , pp. -
508 views Abstract
2020
Radiotheranostics: a roadmap for future development.
Herrmann, Ken;Schwaiger, Markus;Lewis, Jason S;Solomon, Stephen B;McNeil, Barbara J;Baumann, Michael;Gambhir, Sanjiv S;Hricak, Hedvig;Weissleder, Ralph;
Vol. 21 , No. 3 , pp. e146-e156
487 views DOI Abstract
2019
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Giuliano, Mario;Schettini, Francesco;Rognoni, Carla;Milani, Manuela;Jerusalem, Guy;Bachelot, Thomas;De Laurentiis, Michelino;Thomas, Guglielmo;De Placido, Pietro;Arpino, Grazia;De Placido, Sabino;Cristofanilli, Massimo;Giordano, Antonio;Puglisi, Fabio;Pistilli, Barbara;Prat, Aleix;Del Mastro, Lucia;Venturini, Sergio;Generali, Daniele;
365 views DOI Abstract
2016
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
Dimopoulos, Meletios A;Moreau, Philippe;Palumbo, Antonio;Joshua, Douglas;Pour, Ludek;Hájek, Roman;Facon, Thierry;Ludwig, Heinz;Oriol, Albert;Goldschmidt, Hartmut;Rosiñol, Laura;Straub, Jan;Suvorov, Aleksandr;Araujo, Carla;Rimashevskaya, Elena;Pika, Tomas;Gaidano, Gianluca;Weisel, Katja;Goranova-Marinova, Vesselina;Schwarer, Anthony;Minuk, Leonard;Masszi, Tamás;Karamanesht, Ievgenii;Offidani, Massimo;Hungria, Vania;Spencer, Andrew;Orlowski, Robert Z;Gillenwater, Heidi H;Mohamed, Nehal;Feng, Shibao;Chng, Wee-Joo;, ;
Vol. 17 , No. 1 , pp. 27-38
351 views DOI Abstract
2016
Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial.
Neal, Joel W;Dahlberg, Suzanne E;Wakelee, Heather A;Aisner, Seena C;Bowden, Michaela;Huang, Ying;Carbone, David P;Gerstner, Gregory J;Lerner, Rachel E;Rubin, Jerome L;Owonikoko, Taofeek K;Stella, Philip J;Steen, Preston D;Khalid, Ahmed Ali;Ramalingam, Suresh S;, ;
Vol. 17 , No. 12 , pp. 1661-1671
342 views DOI Abstract
2020
Glioma patient-reported outcome assessment in clinical care and research: a Response Assessment in Neuro-Oncology collaborative report.
Armstrong, Terri S;Dirven, Linda;Arons, David;Bates, Amanda;Chang, Susan M;Coens, Corneel;Espinasse, Claire;Gilbert, Mark R;Jenkinson, David;Kluetz, Paul;Mendoza, Tito;Rubinstein, Larry;Sul, Joohee;Weller, Michael;Wen, Patrick Y;van den Bent, Martin J;Taphoorn, Martin J B;
Vol. 21 , No. 2 , pp. e97-e103
313 views DOI Abstract
2013
Is India ready to lead the battle for fair access to medicines?
Lancet Oncology, ;
Vol. 14 , No. 6 , pp. 437
245 views DOI
2019
Erratum: Correction to Lancet Oncol 2019; 20: 408-19 (The Lancet. Oncology (2019) 20 3 (408-419) PII: S1470-2045(19)30587-X)
not, found
Vol. 20 , pp. e559
218 views DOI
2010
Pancreatic cancer: a neglected killer?
Lancet Oncology, ;
Vol. 11 , No. 12 , pp. 1107
210 views DOI
2020
Radiotheranostics: a roadmap for future development.
Herrmann, Ken;Schwaiger, Markus;Lewis, Jason S;Solomon, Stephen B;McNeil, Barbara J;Baumann, Michael;Gambhir, Sanjiv S;Hricak, Hedvig;Weissleder, Ralph;
Vol. 21 , No. 3 , pp. e146-e156
487 views DOI Abstract
2020
Glioma patient-reported outcome assessment in clinical care and research: a Response Assessment in Neuro-Oncology collaborative report.
Armstrong, Terri S;Dirven, Linda;Arons, David;Bates, Amanda;Chang, Susan M;Coens, Corneel;Espinasse, Claire;Gilbert, Mark R;Jenkinson, David;Kluetz, Paul;Mendoza, Tito;Rubinstein, Larry;Sul, Joohee;Weller, Michael;Wen, Patrick Y;van den Bent, Martin J;Taphoorn, Martin J B;
Vol. 21 , No. 2 , pp. e97-e103
313 views DOI Abstract
2019
Erratum: Correction to Lancet Oncol 2019; 20: 408-19 (The Lancet. Oncology (2019) 20 3 (408-419) PII: S1470-2045(19)30587-X)
not, found
Vol. 20 , pp. e559
218 views DOI
2019
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Giuliano, Mario;Schettini, Francesco;Rognoni, Carla;Milani, Manuela;Jerusalem, Guy;Bachelot, Thomas;De Laurentiis, Michelino;Thomas, Guglielmo;De Placido, Pietro;Arpino, Grazia;De Placido, Sabino;Cristofanilli, Massimo;Giordano, Antonio;Puglisi, Fabio;Pistilli, Barbara;Prat, Aleix;Del Mastro, Lucia;Venturini, Sergio;Generali, Daniele;
365 views DOI Abstract
2017
Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study
Chiappella A;Martelli M;Angelucci E;Brusamolino E;Evangelista A;Carella AM;Stelitano C;Rossi G;Balzarotti M;Merli F;Gaidano G;Pavone V;Rigacci L;Zaja F;D'Arco A;Cascavilla N;Russo E;Castellino A;Gotti M;Congiu AG;Cabras MG;Tucci A;Agostinelli C;Ciccone G;Pileri SA;Vitolo U;;
Vol. 18 , No. 8 , pp. -
508 views Abstract
2016
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
Dimopoulos, Meletios A;Moreau, Philippe;Palumbo, Antonio;Joshua, Douglas;Pour, Ludek;Hájek, Roman;Facon, Thierry;Ludwig, Heinz;Oriol, Albert;Goldschmidt, Hartmut;Rosiñol, Laura;Straub, Jan;Suvorov, Aleksandr;Araujo, Carla;Rimashevskaya, Elena;Pika, Tomas;Gaidano, Gianluca;Weisel, Katja;Goranova-Marinova, Vesselina;Schwarer, Anthony;Minuk, Leonard;Masszi, Tamás;Karamanesht, Ievgenii;Offidani, Massimo;Hungria, Vania;Spencer, Andrew;Orlowski, Robert Z;Gillenwater, Heidi H;Mohamed, Nehal;Feng, Shibao;Chng, Wee-Joo;, ;
Vol. 17 , No. 1 , pp. 27-38
351 views DOI Abstract
2016
Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial.
Neal, Joel W;Dahlberg, Suzanne E;Wakelee, Heather A;Aisner, Seena C;Bowden, Michaela;Huang, Ying;Carbone, David P;Gerstner, Gregory J;Lerner, Rachel E;Rubin, Jerome L;Owonikoko, Taofeek K;Stella, Philip J;Steen, Preston D;Khalid, Ahmed Ali;Ramalingam, Suresh S;, ;
Vol. 17 , No. 12 , pp. 1661-1671
342 views DOI Abstract
2013
Is India ready to lead the battle for fair access to medicines?
Lancet Oncology, ;
Vol. 14 , No. 6 , pp. 437
245 views DOI
2010
Pancreatic cancer: a neglected killer?
Lancet Oncology, ;
Vol. 11 , No. 12 , pp. 1107
210 views DOI
0
Overall
Not Rated
0
0
0
0
0
0
0
0
0
0
0
Journament